PU AD companion diagnostic

Drug Profile

PU AD companion diagnostic

Alternative Names: PU-AD PET enhancer; PU-AD positron emission tomography enhancer; PU-AD-PET

Latest Information Update: 29 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Samus Therapeutics
  • Class Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Alzheimer's disease
  • Preclinical Brain injuries

Most Recent Events

  • 30 Mar 2017 Phase-I clinical trials in Alzheimer's disease (Diagnosis) in USA
  • 30 Mar 2017 Preclinical trials in Brain injuries in USA
  • 30 Mar 2017 Samus Therapeutics plans to file an IND application for Alzheimer's disease and Brain injuries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top